Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neihulizumab - AltruBio

Next Previous
X
Search
Drug Profile

Neihulizumab - AltruBio

Alternative Names: AbGn-168; AbGn-168H; ALTB-168; Antibody-168

Latest Information Update: 19 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbGenomics Corporation
  • Developer AltruBio; Boehringer Ingelheim; Stanford University
  • Class Anti-inflammatories; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; P-selectin ligand protein stimulants; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
  • Phase I Graft-versus-host disease
  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 19 Jun 2023 Pharmacodynamics data from a preclinical study in Graft-versus-host disease were released by AltruBio
  • 08 May 2023 Updated efficacy data from a phase II trial in Ulcerative colitis released by AltruBio
  • 07 Mar 2023 AltruBio terminates a phase II trial in Ulcerative colitis in Puerto Rico and USA (IV), due to operational difficulties associated with COVID-19 pandemic (NCT03298022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top